Leerink Partnrs Issues Optimistic Forecast for AXSM Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Investment analysts at Leerink Partnrs raised their Q1 2025 EPS estimates for shares of Axsome Therapeutics in a research report issued to clients and investors on Tuesday, February 18th. Leerink Partnrs analyst M. Goodman now forecasts that the company will earn ($1.31) per share for the quarter, up from their prior forecast of ($1.48). The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.26) per share. Leerink Partnrs also issued estimates for Axsome Therapeutics’ Q2 2025 earnings at ($1.30) EPS, Q3 2025 earnings at ($1.12) EPS, Q4 2025 earnings at ($0.72) EPS, FY2025 earnings at ($4.45) EPS, FY2026 earnings at ($1.25) EPS and FY2027 earnings at $4.10 EPS.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.01. The firm had revenue of $118.77 million for the quarter, compared to analysts’ expectations of $117.83 million. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%.

Other research analysts have also issued reports about the stock. William Blair restated an “outperform” rating on shares of Axsome Therapeutics in a report on Tuesday. Bank of America raised their target price on shares of Axsome Therapeutics from $143.00 to $167.00 and gave the stock a “buy” rating in a research report on Tuesday, February 11th. Mizuho raised their target price on shares of Axsome Therapeutics from $137.00 to $195.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 11th. HC Wainwright raised their target price on shares of Axsome Therapeutics from $190.00 to $200.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Leerink Partners raised their target price on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the stock an “outperform” rating in a research report on Monday, February 10th. One equities research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $157.64.

Axsome Therapeutics Price Performance

NASDAQ:AXSM opened at $137.75 on Friday. The firm has a market cap of $6.72 billion, a price-to-earnings ratio of -23.00 and a beta of 1.05. The company has a current ratio of 2.11, a quick ratio of 2.37 and a debt-to-equity ratio of 3.22. The company’s 50-day moving average is $101.29 and its two-hundred day moving average is $94.84. Axsome Therapeutics has a 12-month low of $64.11 and a 12-month high of $139.13.

Institutional Investors Weigh In On Axsome Therapeutics

Several institutional investors have recently bought and sold shares of AXSM. Boxer Capital Management LLC acquired a new stake in Axsome Therapeutics in the fourth quarter worth about $39,767,000. Lazard Asset Management LLC raised its position in Axsome Therapeutics by 525.7% in the fourth quarter. Lazard Asset Management LLC now owns 537,669 shares of the company’s stock worth $45,492,000 after acquiring an additional 451,737 shares in the last quarter. Norges Bank bought a new stake in Axsome Therapeutics in the fourth quarter worth about $34,100,000. BVF Inc. IL raised its position in Axsome Therapeutics by 32.7% in the fourth quarter. BVF Inc. IL now owns 1,388,064 shares of the company’s stock worth $117,444,000 after acquiring an additional 342,064 shares in the last quarter. Finally, Iron Triangle Partners LP bought a new stake in Axsome Therapeutics in the third quarter worth about $22,671,000. Institutional investors and hedge funds own 81.49% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Nick Pizzie sold 3,000 shares of the business’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $131.07, for a total transaction of $393,210.00. Following the completion of the transaction, the chief financial officer now owns 42,187 shares of the company’s stock, valued at approximately $5,529,450.09. The trade was a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 22.40% of the stock is currently owned by corporate insiders.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.